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SUMMARY 
Background:  The high rates of recurrent tuberculosis and HIV in Kenya raised the assumption that anti	
tuberculosis drug resistance may be an increasing problem. 
Objective: To determine whether HIV co	infection and TB recurrence are associated with anti	TB drug 
resistance.  Methods: Cross	sectional study in which sputa from 872 TB suspects underwent ZN smear 
microscopy and culture.  Growth was identified using Hain molecular identification kits.  Screening for HIV 
infection was done using Uni	GoldTM rapid test and the positives confirmed with enzyme linked immunosorbent 
assay.   
Results:  A total of 186 M. tuberculosis complex and 15 non	tuberculous mycobacteria isolates were obtained.  
The tuberculosis recurrence and TB	HIV co	infection rates amounted to 44.8% and 41.8%, respectively.  All the 
186 M. tuberculosis isolates were susceptible to streptomycin and ethambutol.  Only 12 (6.5%) of the isolates 
were mono	drug resistant, nine to isoniazid and three to rifampicin.  Only 3/27 isoniazid resistant isolates were 
from recurrent TB cases.   
Conclusion and recommendation:  No MDR strains of M. tuberculosis were observed in the current study.  
However, the study suggests an association between HIV co	infection and anti	TB mono drug resistance.  High 
TB recurrence observed in the current study was not associated with anti	TB drug resistance.  What needs to be 
examined is the cause of this high TB recurrence rate in Western Kenya. 
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Introduction 
The increasing global spread of multidrug resistant TB 
(MDRTB), defined as resistance to at least isoniazid 
and rifampicin adversely affects patient care and public 
health [13].  Multidrug resistance has been identified 
a severe threat with a strong impact on morbidity and 
mortality, lengthy treatment periods and financial burden 
[1].  Extensively drug resistant TB (XDRTB), defined as 
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MDRTB with additional resistance to a fluoroquinolone 
and at least one of the three secondline injectable 
drugs, capreomycin, kanamycin and amikacin, has been 
identified in many countries including South Africa, USA, 
Europe and former Soviet countries [3].  At least 17 
countries have reported XDRTB cases among which 
mortality is extremely high.  The XDRTB leaves 
patients virtually untreatable using currently available 
antiTB drugs [46]. 
The development and transmission of MDRTB is 
fanned by many factors, which include HIV infection [7
10], inappropriate chemotherapy such as failure to 
detect resistance to antiTB drugs, extensive 
prophylactic use of the antiTB drugs on TB infected 
HIV/AIDS patients, noncompliance with chemotherapy 
by TB patients [1113] and increasing poverty and its 
associated factors such as overcrowding and 
malnutrition [14].  Outbreaks of drugresistant TB 
among HIVpositive patients have been widely 
documented in nosocomial and other congregate 
settings [15, 16].  However, little information is available 
about the association of HIV and drugresistant TB at 
population level [15].  The MDRTB ‘M’ strain has been 
reported to cause nosocomial outbreaks among 
HIV/AIDS cases in Buenos Aires, Argentina, with the 
infection spreading to nearby health centres [8].  In the 
USA, the highly resistant Beijing ‘W’ strain has caused 
several nosocomial outbreaks in New York, with 
mortality rates above 80%, the majority (73%) being 
HIV/AIDS cases [7, 17].  In this same city, MDRTB 
was diagnosed in 241 patients in the period of 1995 
through 1997, majority of whom (90%) had no prior 
treatment history.  The majority of MDRTB patients 
(53.1%) had HIV infection compared with nonMDRTB 
patients (31.2%) [16]. In Russia, MDRTB caused by 
Beijing strains is prevalent in crowded prisons, a 
significant number of the affected being HIVinfected 
[18].  Surveys in Latvia and Ukraine indicate the level of 
MDRTB among TB patients living with HIV to be 
almost twice compared with TB patients without HIV [3]. 
The association between HIV coinfection and antiTB 
drug resistance may be attributed to the acquisition of 
rifampicin resistance among the HIV positive people 
under treatment for TB [19], although this may also be 
due to disruptions in therapy and malabsorption of the 
antiTB drugs in HIV positive patients, which suggests 
that HIV positive TB patients may be at greater risk of 
acquiring drug resistance [9].  The other reason for 
higher chance of HIV positives to contract drug resistant 
TB (DRTB) relates to the higher risk of exposure 
during hospitalization, when they interact with drug
resistant TB patients [19].  However, history of prior TB 
treatment remains the most important risk factor for DR
TB [20].  The high case fatality rates of MDR and XDR
TB in HIV coinfected patients could have devastating 
and demoralizing effects on health care workers and 
communities [21]. 
Previous studies indicate that MDRTB occurs 5 – 10
fold more frequently in patients previously treated for TB 
than among new TB cases [22].  Surveys in some 
African countries performed from 1999 through 2002 
demonstrated a median prevalence of mono drug 
resistance among previously treated TB cases of 16.7% 
(range, 0% – 30.3%).  The median rate of MDR TB 
among them was 5.9% (range, 0%–13.7%) [23].   A 
recent national survey in Rwanda found that 9.4% of 
treatmentexperienced patients with TB had MDR TB 
[24].  In a referral center in Addis Ababa, Ethiopia, the 
prevalence of MDR TB among previously treated 
patients with TB was 12% [25].  Most recently, the 
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WHO reported that 16% of recurring cases in Senegal 
involve MDR TB, albeit the estimate based on a small 
sample size [26].  The present study was done to 
determine whether HIV coinfection and TB recurrence 
are associated with antiTB drug resistance in western 
Kenya. 
    
Materials and Methods 
Study Design:  A crosssectional study was conducted 
between September 2007 and September 2009.  
 
Study site and population:  The study was done at 
chest and paediatric clinics at one provincial, one level 5 
hospital and eight district hospitals in western Kenya.  
These were Busia, Bungoma, Kisumu, Migori, Kisii 
(Level 5), Narok, Kericho, Uasin Gishu and Lodwar 
district hospitals, and Nakuru Provincial General 
Hospital.  Western Kenya includes the expansive former 
Rift Valley, Nyanza and Western Provinces, with a 
cumulative population of about 19.8 million people, 
constituting about 52.1% of the Kenyan population. 
 
Sampling frame and patient characteristics: 
Participants suspected of having pulmonary TB were 
enrolled into the study between September 2007 and 
September 2009 as they sought healthcare services at 
the chest and paediatric clinics.  They had to be 
resident in western Kenya for at least six months and 
consented to participate in the study.  Cases that had 
prior treatment were carefully screened and those 
already on antiTB were excluded.  Participants were 
suspected of having TB if they fulfilled the National TB 
Progemme criteria: had a cough of more than two 
weeks and were not responding to antibiotic treatment 
[27]. 
Collection of demographic data:  A questionnaire was 
used to obtain participant demographic data.  Data 
collected included age, gender, previous antiTB 
treatment, HIV status, and antiretroviral therapy (ART). 
 
Collection of sputum and blood samples:  Three 
sputum specimens (spot, early morning, spot) were 
collected from 872 TB suspects with under the 
supervision of trained and competent medical staff.  The 
patients were requested to cough so that expectoration 
would come from deep down the chest as possible, and 
spit into a sterile 50 ml blue cap tubes.  For children 
less than 5 years of age and those less than 10 years 
of age unable to expectorate sputum had sputum 
induction performed at the Nakuru provincial and Kisii 
level 5 hospitals.  The sputum induction involving six (6) 
children was done by paediatricians using hypertonic 
(3%) saline [28]. The samples were refrigerated at 4oC 
awaiting transportation in cool boxes to the Mycobacteria 
Reference Laboratory, Moi University School of Medicine 
(MRL, MUSOM) weekly for analysis (ZN smear 
microscopy, culture, identification of isolates and drug 
susceptibility testing).  Samples were processed within 7 
days of collection in order to minimize loss of viability of 
the mycobacteria.  Consenting 695 participants also 
underwent phlebotomy for HIV testing.  The blood was 
delivered into Vacutainer Brand STERILE interior EDTA 
(K3) tubes and stored at –20oC awaiting processing.  
The samples were transported in cool boxes to MRL, 
MUSOM, Eldoret, and processed within two weeks.  The 
safety for research assistants and healthcare workers 
during collection and handling of sputum specimens was 
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HIV testing:  Screening for HIV infection was done by 
screening serum/plasma by the Trinity Biotech Uni
GoldTM test [30] and confirmed with the enzyme linked 
immunosorbent assay (ELISA) [31], following 
manufacturers’ instructions.    
 
Identification of recurrent TB cases:  A questionnaire 
was used to obtain information on subjects who had 
history of TB treatment.  Those who indicated to have 
been previously treated for TB and declared cured and 
renotified at least 12 months from the date of the initial 
notification were considered recurrent TB cases [32], 
after verification of their records held at the hospital. 
 
Microscopic examination of specimens:  Sputum 
smears were examined for acidfast bacilli (AFB) after 
staining with carbolfuchsin using the ZiehlNeelsen 
(ZN) method [33].  A TB suspect was considered to be 
ZN smear positive if at least one of the three specimens 
was ZN smear positive. 
 
Isolation of mycobacteria and identification of 
mycobacteria:  Sputum specimens were processed for 
isolation of mycobacteria following standard protocols 
[34].  The mycobacterial isolates were identified as M. 
tuberculosis complex or species of nontuberculous 
mycobacteria (NTM) using Hain’s GenoType® 
Mycobacterium CM and GenoType® Mycobacterium AS 
Molecular Genetic Assays, following manufacturer’s 
instructions [35].  
 
Anti	TB drug susceptibility testing:  The isolates 
underwent drug susceptibility testing (DST) for INH and 
RIF using the Hain’s GenoType® MTBDRplus Molecular 
Genetic Assay [35], and for STR, INH, RIF, and EMB 
using the BACTEC MGIT 960 SIRE kit [34].  
Data analysis:  Data was entered in MS Excel 8.0 and 
analysed using Epi Info version 3.5.1 to calculate 
proportions. 
   
Ethical issues:  Ethical issues:  The proposal for this 
study was approved by ITROMID / KEMRI’s Scientific 
Steering Committee (SSC) and Ethical Review 
Committee (ERC) [SSC No. 837] and by Moi University 
School of Medicine (MUSOM) / Moi Teaching and 
Referral Hospital (MTRH) Institutional Research and 
Ethics Committee (IREC) [FAN No.00092]. The study 
was conducted in accordance with the Declaration of 
Helsinki [36]. Results on TB, NTM disease and HIV 
infection were availed to respective healthcare givers for 
appropriate patient care. The HIV positive cases were 




Study participants: A total of 872 TB suspects were 
enrolled in the study at the 10 study sites; 54.9% (477) 
males and 45.1% (393) females.  The ages of the 
suspects were between 9 months and 80 years, the 
median age being 32 years.  The majority (33.1%) of 
the suspects were in the 2534 agegroup, followed by 
those in the 3544 (21.8%) and 1524 (18.7%) age
groups, respectively.  Children in the 014 agegroup 
constituted 4.6%, with the under fives (<5 years) 
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Table 1 Study population and genderage distribution  
Age	group N (%) Males (%) Females (%) 
014 40(4.6) 22(2.5) 18(2.1) 
1524 163(18.7) 80(9.2)  83(9.5) 
2534 288(33.0) 162(18.5) 126(14.4) 
3544 190(21.8) 108(12.4) 82(9.4) 
4554 89(10.2) 53(6.1) 36(4.1)  
5564 54(6.2) 29(3.3)  25(2.9)  
> 64 48(5.5) 25(2.9)  23(2.6)  
Total 872(100) 479(54.9) 393(45.1) 
Key: N = Number of tuberculosis suspects 
Mycobacterial disease and recurrent TB:  Sputum 
samples from 39.1% (341/872) cases were ZN smear 
positive, of which 53.1% (181/341) were culture 
positive.  Only 3.8% (20/531) of the ZN smear 
negatives were culture positive.  Hence, 41.4% 
(361/872) cases were suspected to have mycobacterial 
disease, of which 44.3% (160/361) were culture 
negative and 55.7% (201/361) were culture positive.   
Of the culture positives, 92.5% (186/201) were 
identified as M. tuberculosis complex and 7.5% were 
NTM.  The 42.6% ZN smear positive but culture 
negative cases were also regarded and treated as TB 
irrespective bacteriological confirmation.  However, no 
followup was done to determine the treatment 
outcome.  No cultures yielded both tuberculous and 
nontuberculous mycobacteria (Table 2). A total of 155 
(42.9%) of the 361 mycobacterial infection cases were 
recurrent TB, having previously been treated for TB and 
declared cured.  Four of the NTM infection cases had 
previously been treated for TB.  The remaining 202 
mycobacterial infection cases were new. The data 
collected in questionnaire regarding previous treatment 
was in agreement with hospital records. 
HIV infection:  A total of 244 (35%) of the participants 
knew and correctly revealed their HIV status during 
enrolment into the study (39 seropositive and 205 
seronegative) but still accepted to undergo another HIV 
test.  In total 272 participants of the 695 tested for HIV 
infection were seropositive.  Among the 361 
mycobacterial disease cases (TB and NTM), 75.9% 
(274/361) accepted to be tested for HIV infection of 
which 42.7% (117/274) were HIV positive, and 24.1% 
(87/361) declined HIV testing. Only 16.9% (46/272) of 
the HIV/AIDS cases were on antiretroviral therapy 
(ART), 65.2% females and 34.8% males (Table 2). 
Table 2 ZN microscopy, cultures and HIV infection 
 
N = 695 
ZN smear microscopy culture 
ZN smear positive ZN smear negative Culture positive Culture negative 
HIV positive 109 163 78 194 
HIV negative 146 277 90 333 
Totals 255 440 168 527 
 
53 
Journal of Health Sciences, Volume 24, Number 1, JanuaryMarch 2013 
 
HIV co	infection, TB recurrence and anti	TB drug 
resistance:  Of the 186 M. tuberculosis complex 
isolates subjected to antiTB drug susceptibility testing, 
85.5% (159/186) were from new TB cases and 14.5% 
(27/186) from recurrences. All the isolates were 
susceptible to STR and EMB with the BACTEC MGIT 
960 DST.  Both the Hain’s GenoType® MTBDRplus and 
the BACTEC MGIT 960 DST gave the results on 
rifampicin (RIF) and isoniazid (INH) resistance; only 
6.5% (12/186) of the isolates were monodrug 
resistant, nine (75%) to INH, and three (25%) to RIF.  
All the three isolates resistant to RIF were from new 
female cases coinfected with HIV, none of whom was 
on antiretroviral therapy (ART).  Of the nine (9) isolates 
resistant to INH, three were from recurrences co
infected with HIV, and six were from new cases, four of 
whom were HIV negative, one coinfected with HIV, and 
one with unknown HIV status; one new case with isolate 
resistant to INH was on ART. 
 
Discussion 
The present study observed 6.5% of the M. tuberculosis 
complex isolates to be monodrug resistant to either to 
isoniazid (75%) or rifampicin (25%).  However, this is 
unlike the 2008 and 2009 annual reports of the DLTLD 
[37, 38] which report MDRTB cases. In 2008 the 
DLTLD reported 1.82% (102/5604) of M. tuberculosis 
complex isolates examined to be resistant multidrug 
resistant.  In 2009, 2.3% (150/6569) of the TB cases 
reported by the DLTLD had MDR strains of M. 
tuberculosis complex, with one XDRTB case isolated 
and initiated on treatment at the Moi Teaching and 
Referral Hospital (MTRH), Eldoret.  At the same time, 
the WHO [3] reported global X/MDRTB cases to be 
5.1% of the total cases. The plausible explanation for 
the much lower resistance levels and no MDRTB cases 
observed in the present study compared to the DLTLD 
report is that the latter deals with retreatment cases 
(relapses and treatment failures) country wide. However, 
recurrences can be either relapses (endogenous 
reactivation), or exogenous reinfections. A relapse (R) 
is defined as a smearpositive TB patient who has 
previously been treated and declared cured.  Treatment 
failure (TF) is a patient with a positive smear at the end 
of five months despite being on antiTB treatment, 
hence failing to respond to treatment [39]. The 
probability of antiTB drug resistance is higher in 
relapses and treatment failures.  However, there is a 
small relapse rate associated with all treatment 
regimens, even if the treatment has been taken 
religiously with 100% compliance (the standard regimen 
2HREZ/4HR has a relapse rate of 2 to 3%).  The 
majority of relapses occur within 12 months of 
completing treatment [40]. 
 
However, the findings of the present study compares 
well with a previous study in Kenya by Githui et al. [41] 
which reported a national antimycobacterials resistance 
rate of 6.3% among isolates from TB cases without 
history of prior chemotherapy, and a resistance rate of 
37% among those previously treated.  However, in 
another study three years later on refugee and non
refugee populations in North Eastern Kenya, Githui et al. 
[42] reported 18% resistance to one or more drugs, and 
an MDRTB rate of 2.9% among the examined isolates.  
The resistance rate among the neighbouring non
refugee populations was 5.7%, with no MDRTB 
causing strains observed.    
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The present study observes that the drug isoniazid (INH) 
to be loosing ground in the fight against TB. Among the 
monodrug resistant M. tuberculosis complex isolates 
observed in the present study, 75% were resistant to 
INH.  Although INH resistance in general is a negative 
risk factor for transmission of TB [43], and the virulence 
of most INH resistant strains may be reduced, multi
drugresistant M. tuberculosis complex strains can be 
as infectious and virulent as drugsusceptible strains 
[44], and the clinical presentation of MDRTB is similar 
to that of drug susceptible TB.  However, MDRTB is 
difficult to treat and associated with a poor prognosis 
[45].  Even though drug resistant strains of M. 
tuberculosis complex isolated in the present study 
constituted only 6.5%, the majority (66.7%) were from 
TBHIV cases, suggesting a possible association 
between HIV coinfection and antiTB drug resistance.  
Kenya continues to treat more and more TB patients 
each year. However, widespread coinfection with HIV 
(close to 48 percent of new TB patients) makes TB 
treatment difficult. While the number of new cases 
appears to be declining, the number of patients requiring 
retreatment has increased [38].  What is not clear is 
whether the cases requiring retreatment are due to 
relapse or it could involve an underestimated 
contribution of reinfection.  
 
Conclusions and Recomendation 
No MDRTB cases were reported in the present study, 
and the firstline antiTB drugs can still be used for 
effective treatment of TB cases in western Kenya.  
About 67% of monodrug resistant M. tuberculosis 
isolates were from TBHIV cases, suggesting an 
association between HIV coinfection with antiTB mono 
drug resistance.  TB recurrence was not associated with 
antiTB drug resistance.  What needs to be examined is 
the cause of the high recurrence rate in western Kenya, 
whether it is due to exogenous reinfection or 
endogenous reactivation (relapse). 
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